image credit- shutterstock
A cross-sectional study was recently conducted to clarify the adverse events of COVID-19 vaccines in Japanese young population.
Currently, in Japan, the COMIRNATY (Pfizer) intramuscular injection is used for priority vaccinations, and COVID-19 Vaccine Moderna Intramuscular Injection is used for vaccination in workplaces.
The study population included people who had a first time vaccination using COVID-19 Vaccine Moderna Intramuscular Injection.
The researchers analyzed 1,877 data obtained from a questionnaire survey of 1,993 vaccinated individuals. Eighty-two percent of participants complained of local adverse events such as headache, fatigue, nausea. Injection site pain was the most common local adverse event (71%). Systemic adverse events occurred in 48% of participants. The most common adverse event was myalgia or muscle pain (34%).
The results of this study clarified for the first time that age less than 20 years is a risk factor for systemic adverse events from the COVID-19 Vaccine Moderna Intramuscular Injection.
This information will give impacts on considering adverse events and its mechanisms in mRNA vaccination.
